Raab promises blockbuster IPO

Ebb & Flow

Raab promises blockbuster IPO

Sinogen International, a Chinese manufacturer and distributor of alpha interferon, is looking to do an IPO next year, according to Chairman Kirk Raab, who warns investors to brace for a boffo offering. "It will be one of the biggest IPOs the industry has seen," the former Genentech president and CEO told Ebb & Flow. "It's not a pure biotech play - it's also a China play, and an emerging markets play. A lot of funds would be interested in it." Look for a multiple listing also. "The thought process is that we would list on NASDAQ, and perhaps the London and Hong Kong exchanges as well," he said. The company, which hopes to be profitable this year from its Chinese manufacturing operations, also is setting up a genomics organization. Hambrecht & Quist Asian Pacific Venture Fund is an investor in Sinogen, Raab said.

NASDAQ CAMPAIGN: In a bid

Read the full 1555 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE